PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...
ETHealthworld.com brings latest multiple sclerosis news, views and updates from all top sources for the Indian Health industry.
Investing.com -- UBS downgraded French pharmaceutical giant Sanofi SA (EPA:SASY) to “neutral” from “buy” rating and cut its ...
The upgrade follows positive readouts from one of Roche’s fenebrutinib Phase 3 trials in relapsing multiple sclerosis, known ...
January might offer a new year reset, but chronic illness demands us to move forward and bring what we’ve learned, says ...
News-Medical.Net on MSN
Rare immune events link Epstein Barr virus to early multiple sclerosis damage
The current study shows that the Epstein–Barr virus can interfere with the normal control of B cells. One viral protein ...
Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback